Abstract
Background In the transport sector, efforts to achieve carbon neutrality may generate public health cobenefits by promoting physical activity.
Objective This study aims to quantify the health impacts related to active transportation based on four different scenarios leading France toward carbon neutrality in 2050.
Methods The French Agency for Ecological Transition developed four consistent and contrasting scenarios (Transitions2050 scenarios: S1 to S4) achieving carbon neutrality by 2050 as well as a business-as-usual (BAU) scenario that extends our current lifestyles until 2050, without reaching net-zero. For each Transitions2050 scenario, we distributed the mobility demand for walking, cycling and e-cycling across age groups. Relying on the health impact assessment framework, we quantified the impacts of the corresponding physical activity on all-cause mortality. The impact of each of the carbon neutrality scenarios was determined by comparison with estimates from the BAU scenario.
Results In S1 and S2 scenarios, volumes of active transportation are projected to increase to fulfil the World Health Organisations recommendations by 2050, while they increase slightly in S3 and decrease in S4. S2 scenario reaches the highest levels of health cobenefits, with 497,000 deaths prevented between 2021 and 2050. This would translate into a life expectancy gain of 3.0 months for the general population in 2050, mainly driven by e-bikes. S1 would provide smaller but important health benefits, while these benefits would be modest for S3. On the contrary, S4 implies 52,000 additional deaths as compared to the BAU scenario, and a loss of 0.2 month in life expectancy.
Discussion Different ways to decarbonize mobility in a net-zero perspective may achieve very contrasting public health cobenefits. This study illustrates how the public health dimension may provide a relevant insight in choices of collective transformation toward net-zero societies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
all data and codes are publicly available at
